
|Videos|June 17, 2014
Charles M. Perou, PhD, Discusses Genomic Signatures and Dual HER2-Targeting in Breast Cancer
Charles M. Perou, PhD, professor of genetics, pathology & laboratory medicine, UNC Lineberger Comprehensive Cancer Center, discusses a trial (CALGB 40601) presented at the 2014 ASCO Annual Meeting.
Advertisement
Charles M. Perou, PhD, professor of genetics, pathology & laboratory medicine, UNC Lineberger Comprehensive Cancer Center, discusses a trial (CALGB 40601) presented at the 2014 ASCO Annual Meeting that analyzed gene expression signatures in patients with HER2-positive breast cancer treated with weekly paclitaxel and trastuzumab with or without lapatinib.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
What Pharmacists Need to Know About Retatrutide's TRIUMPH-1 Phase 3 Results
2
First-in-Human In Vivo CAR-T Therapy Shows Encouraging Activity in Relapsed/Refractory Multiple Myeloma
3
FDA Approves Ensitrelvir for Post-Exposure Prophylaxis of COVID-19 in Adolescents and Adults
4
Darovasertib Plus Crizotinib Shows Striking Efficacy in HLA-A2–Negative Metastatic Uveal Melanoma, OptimUM-02 Results Show
5








































































































































